Tefibazumab
Подписчиков: 0, рейтинг: 0
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | Clumping factor A |
| Clinical data | |
| Trade names | Aurexis |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| Chemical and physical data | |
| Formula | C6548H10122N1730O2034S44 |
| Molar mass | 147035.72 g·mol−1 |
|
| |
Tefibazumab (named Aurexis but not approved) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in a phase 2a patients with cystic fibrosis and of methicillin-resistant S. aureus.
It was developed by Inhibitex.
See also
- MSCRAMM (microbial surface components recognizing adhesive matrix molecules)
| Fungal |
|
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Viral | |||||||||
| Bacterial |
|
||||||||
| Toxin |
|
||||||||
| |||||||||